SCHEMBL10140468

SCHEMBL10140468

CCc1ccc(-c2c(OC)c(C(C)=O)nn2C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM2B Q8NHM5 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
ALDH1A1 P00352 1/20 0.36
TDP2 O95551 3/20 0.36
CYP1A2 P05177 1/20 0.36
GRM5 P41594 2/20 0.36
LMNA P02545 1/20 0.36
AURKA O14965 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CCNA1 P78396 1/20 0.36
PDE2A O00408 1/20 0.36
TP53 P04637 2/20 0.35
MAPT P10636 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10140386 0.83 CSF1R (0.43) HSD17B10ALDH1A1CYP1A2GRM5LMNA
SCHEMBL1483023 0.82 KDM2B (0.40) HPGDTSHRHSD17B10KDM2BKDM4C
SCHEMBL10140466 0.78 HPGD (0.41) HPGDTSHRHSD17B10ALDH1A1TDP2
SCHEMBL10172623 0.75 ALDH1A1 (0.52) HPGDTSHRHSD17B10ALDH1A1CYP1A2
SCHEMBL7975505 0.74 CA12 (0.42) HPGDHSD17B10ALDH1A1GRM5LMNA
SCHEMBL10140390 0.73 GRM5 (0.43) HPGDTSHRHSD17B10ALDH1A1CYP1A2
SCHEMBL1483434 0.71 MCL1 (0.40) TSHRHSD17B10ALDH1A1CYP1A2LMNA
SCHEMBL1482990 0.68 HSD11B1 (0.46) HSD17B10ALDH1A1LMNATP53MAPT
SCHEMBL1483665 0.68 RARB (0.47) HSD17B10ALDH1A1LMNATP53MAPT
SCHEMBL1483744 0.68 AKR1C2 (0.40) HPGDTSHRALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS F9, F12, F8 HPGD 340/4885TSHR 2666/4885HSD17B10 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.